Humira

(Adalimumab)

ApprovedMonoclonal antibody

Adalimumab is used to treat inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease by reducing the immune system's inflammatory response. It helps relieve pain, swelling, and other symptoms caused by these autoimmune diseases.[2] Humira is currently approved and in use across 30 indications[4].[1]

Humira is one of 550 monoclonal antibody programs targeting Relapsing Polychondritis. It is currently in Approved.

Indications

417

Total Trials

Active Trials

549

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Relapsing PolychondritisRecruiting

PanuveitisUnknown

Anal FistulaCompleted

Rheumatic DiseaseRecruiting

Psoriasis VulgarisUnknown

Immune System DiseaseUnknown

Takayasu ArteritisRecruiting

FolliculitisNot yet recruiting

StrictureUnknown status

Obstructive Sleep ApneaCompleted

Relapsing PolychondritisPhase 2

Recruiting

PanuveitisPreclinical

Unknown

Anal FistulaApproved

Completed

Rheumatic DiseasePhase 2

Recruiting

Psoriasis VulgarisPreclinical

Unknown

Immune System DiseasePreclinical

Unknown

Takayasu ArteritisApproved

Recruiting

FolliculitisPhase 2

Not yet recruiting

StrictureApproved

Unknown status

Obstructive Sleep ApneaApproved

Completed

Showing 10 of 30 indications

Competition

Competitive Landscape

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Humira

RRanbaxy Laboratories Limited

Approved

7 2

Avastin

Roche

Phase 3

11 3

Rapamune

PPrism Pharmaceuticals

Phase 3

5 4

Lutathera

Novartis

Phase 3

1 5

S1,

CChinese Academy of Medical Sciences

Phase 3

1 6

Romiplostim N01

Qilu Pharmaceutical Co., Ltd.

Phase 3

1 7

HSK39297

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

3 8

Imlifidase

HHansa Biopharma AB

Phase 3

2 9

IBI302

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 10

Rengalin

MMateria Medica Holding

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Uveitis

NCT05105347

Q2 2027

Post-ApprovalRecruiting

Efficacy and Safety

NCT06498089

Q3 2027

Phase 3Active, not recruiting

Rheumatoid Arthritis

NCT02629159

Q4 2027

Phase 2Not yet recruiting

Hidradenitis Suppurativa

NCT07151937

N/ARecruiting

Psoriasis

NCT05503875

Clinical

Trials by Indication[1]

Rheumatoid Arthritis50 trials

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 4·NCT01119859·326 enrolled

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

Completed· AbbVie logo

AbbVie·Phase 3·NCT00195663·799 enrolled

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Completed·UUnknown Sponsor·Phase 3·NCT02760407·1,648 enrolled

Show 47 more trials

An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis

Completed·SSamsung Bioepis Co., Ltd.·Phase 2·NCT02565810·49 enrolled

A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00233571·796 enrolled

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Completed· Gilead logo

Gilead·Phase 3·NCT02889796·1,759 enrolled

Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00603993·88 enrolled

Prospective Study on Intensive Early Rheumatoid Arthritis Treatment

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 4·NCT00480272·251 enrolled

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis

Completed· Novartis logo

Novartis·Phase 3·NCT02744755·353 enrolled

Predictors of the Response to Adalimumab in Rheumatoid Arthritis

Completed·UUniversity Hospital, Rouen·Phase 4·NCT00234234·200 enrolled

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00235872·309 enrolled

Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)

Completed·UUniversity Hospital, Tours·N/A·NCT00497614·8 enrolled

Post-marketing Observational Study in Subjects With Rheumatoid Arthritis

Completed·AAbbott··NCT00234884·3,435 enrolled

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

Completed· AbbVie logo

AbbVie··NCT02668640·55 enrolled

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

Completed· AbbVie logo

AbbVie·Phase 2·NCT01712178·100 enrolled

Quality of Life Study With Adalimumab in Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00234936·200 enrolled

Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE

Completed·NNHS Greater Glasgow and Clyde·N/A·NCT05090124·46 enrolled

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 4·NCT02092467·4,372 enrolled

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Recruiting·UUniversita di Verona·Phase 4·NCT06527534·30 enrolled

Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Completed· Amgen logo

Amgen·Phase 3·NCT01970475·526 enrolled

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

Unknown status·GGeorgetown University·Phase 4·NCT01793519·290 enrolled

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Completed· CSL Behring logo

CSL Behring·Phase 2·NCT01373151·418 enrolled

Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00234845·148 enrolled

RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis

Terminated·TTcLand Expression S.A.··NCT03016260·250 enrolled

A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Completed· AbbVie logo

AbbVie·Phase 2·NCT02141997·222 enrolled

Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate

Completed·AAbbott·Phase 3·NCT00235859·128 enrolled

A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Withdrawn· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT02097264

Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.

Unknown status·OOttawa Hospital Research Institute·Phase 4·NCT05153200·40 enrolled

Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis

Unknown status·HHvidovre University Hospital·Phase 4·NCT00216177·112 enrolled

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

Terminated· Roche logo

Roche·Phase 4·NCT01283971·96 enrolled

A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)

Withdrawn· Merck & Co. logo

Merck & Co.··NCT00724672

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Completed· AbbVie logo

AbbVie·Phase 4·NCT01185288·309 enrolled

A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00448383·6,610 enrolled

A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT01231321·100 enrolled

Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 4·NCT00649922·226 enrolled

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT02557100·80 enrolled

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)

Completed· AbbVie logo

AbbVie·Phase 3·NCT01185301·395 enrolled

Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT02092961·198 enrolled

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

Completed· AbbVie logo

AbbVie·Phase 4·NCT02198651·149 enrolled

A Study in Moderate to Severe Rheumatoid Arthritis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01710358·1,307 enrolled

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 2·NCT00235833·25 enrolled

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche·Phase 2·NCT02833350·578 enrolled

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 2·NCT00550446·386 enrolled

The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.

Completed·SSkane University Hospital·Phase 4·NCT01270087·14 enrolled

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

Active, not recruiting· AbbVie logo

AbbVie·Phase 3·NCT02629159·1,629 enrolled

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).

Completed· Pfizer logo

Pfizer·Phase 3·NCT02480153·597 enrolled

Targeted Ultrasound in Rheumatoid Arthritis

Completed·UUniversity of Leeds·Phase 4·NCT02056184·183 enrolled

SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.

Completed·JJulia Brown·Phase 4·NCT01295151·122 enrolled

A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 2·NCT01225393·211 enrolled

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

Completed· EMD Serono logo

EMD Serono·Phase 2·NCT00595413·311 enrolled

Psoriasis25 trials

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

Completed·CCoherus Oncology, Inc.·Phase 3·NCT02489227·545 enrolled

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAbbott·Phase 3·NCT00237887·1,212 enrolled

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAlvotech Swiss AG·Phase 3·NCT04453137·567 enrolled

Show 22 more trials

A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate

Completed· AbbVie logo

AbbVie·Phase 3·NCT01251614·114 enrolled

Immunoclassification of Psoriasis: a Strategy for Precision Medicine

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05503875·100 enrolled

Effect of Adalimumab Therapy on Psoriasis Patient

Unknown status·SSohag University·N/A·NCT05889338·140 enrolled

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01483599·293 enrolled

A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02016482·217 enrolled

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAbbott·Phase 3·NCT00235820·271 enrolled

MAP Study: Methotrexate and Adalimumab in Psoriasis

Completed·JJeffrey J Crowley MD·Phase 2/3·NCT03217734·56 enrolled

The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis

Unknown status·MMedical University of Vienna·Phase 4·NCT01088165·66 enrolled

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAbbott·Phase 2·NCT00645814·148 enrolled

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAbbott·Phase 2·NCT00646191·137 enrolled

Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01646073·425 enrolled

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

Completed·AAbbott·Phase 4·NCT00735787·81 enrolled

Vascular Inflammation in Psoriasis - Extension Study

Completed·UUniversity of Pennsylvania·Phase 4·NCT01866592·81 enrolled

Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAbbott·Phase 2·NCT00645905·148 enrolled

Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis

Completed·IInnovaderm Research Inc.·Phase 4·NCT00940862·30 enrolled

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

Completed·UUniversity Hospitals Cleveland Medical Center··NCT02330380·26 enrolled

Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment

Completed·AAbbott·Phase 3·NCT00574249·730 enrolled

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

Completed· AbbVie logo

AbbVie·Phase 4·NCT01644396·50 enrolled

BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02694523·684 enrolled

Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT01970488·350 enrolled

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Active, not recruiting·BBiocad·Phase 3·NCT06640517·140 enrolled

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed· UCB logo

UCB·Phase 3·NCT03412747·478 enrolled

Adalimumab13 trials

A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

Completed· AbbVie logo

AbbVie·Phase 2·NCT01502423·61 enrolled

Switching From Adalimumab to Infliximab

Completed·UUniversity Hospital, Ghent··NCT01338740·21 enrolled

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

Completed· Pfizer logo

Pfizer·Phase 1·NCT02237729·362 enrolled

Show 10 more trials

ADALISKIAS: Adalimumab for Acute Disc Prolapse

Unknown status·KKuopio University Hospital·Phase 3·NCT01510548·90 enrolled

A Clinical Study With Adalimumab Biosimilar

Completed·LLaboratorios Richmond S.A.C.I.F.·Phase 1·NCT06291948·150 enrolled

Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks

Unknown status·HHospital Universitario La Paz·Phase 3·NCT04404517·20 enrolled

Adalimumab Microneedles in Healthy Volunteers

Completed·CCentre for Human Drug Research, Netherlands·Phase 1/2·NCT03607903·24 enrolled

Therapeutic Monitoring of Infliximab and Adalimumab

Unknown status·IIRCCS Burlo Garofolo··NCT06033469·100 enrolled

Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

Completed· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 1·NCT03357939·220 enrolled

Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD

Withdrawn·MMcMaster University·Phase 4·NCT03059849

Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease

Completed· AbbVie logo

AbbVie·Phase 4·NCT02148718·100 enrolled

Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease

Completed·GGrupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa·Phase 3·NCT01564823·86 enrolled

A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects

Completed·MMeiji Seika Pharma Co., Ltd.·Phase 1·NCT02927353·180 enrolled

Crohn's Disease12 trials

Remission in Subjects With Crohn's Disease, Open Label Extension

Completed·AAbbott·Phase 3·NCT01070303·177 enrolled

Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

Completed·AAbbott·Phase 3·NCT00105300·300 enrolled

Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115

Completed· AbbVie logo

AbbVie·Phase 3·NCT02185014·252 enrolled

Show 9 more trials

Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants

Terminated·GGrupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa·Phase 3·NCT01562951·15 enrolled

Reduce Risk for Crohn's Disease Patients

Completed·PPIBD-Net·Phase 4·NCT02852694·192 enrolled

Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Completed·AAbbott·Phase 3·NCT00077779·854 enrolled

A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

Completed·AAbbott·Phase 2/3·NCT00445432·82 enrolled

A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

Completed·AAbbott·Phase 2/3·NCT00445939·90 enrolled

Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial

Completed·SSchneider Children's Medical Center, Israel·Phase 4·NCT02256462·82 enrolled

A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease

Withdrawn· UCB logo

UCB·Phase 3·NCT04643483

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

Completed·AAbbott·Phase 3·NCT00195715·777 enrolled

Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)

Completed·—··NCT04131504·239 enrolled

Psoriatic Arthritis10 trials

Ultrasound Enthesitis Response in Psoriatic Arthritis

Completed·BBelfast Health and Social Care Trust··NCT03955861·80 enrolled

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT03151551·566 enrolled

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

Completed· Novartis logo

Novartis·Phase 3·NCT02745080·853 enrolled

Show 7 more trials

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

Terminated· Gilead logo

Gilead·Phase 3·NCT04115748·67 enrolled

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

Completed· AbbVie logo

AbbVie·Phase 2·NCT02349451·240 enrolled

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Completed·AAbbott·Phase 2·NCT00646386·315 enrolled

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Completed· AbbVie logo

AbbVie·Phase 3·NCT03104400·1,705 enrolled

Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial

Completed·UUniversity of Oxford·Phase 4·NCT03739853·192 enrolled

Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients

Not yet recruiting·EEgymedicalpedia··NCT06370156·100 enrolled

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01695239·417 enrolled

42 more indications

Ankylosing Spondylitis9 trials

The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients

Unknown status·QQilu Hospital of Shandong University·Phase 4·NCT05527444·100 enrolled

REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)

Unknown status·HHanyang University Seoul Hospital·Phase 4·NCT05164198·448 enrolled

Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity

Completed·UUniversity Hospital, Montpellier·N/A·NCT01610947·398 enrolled

Show 6 more trials

Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients

Completed· AbbVie logo

AbbVie··NCT02333383·201 enrolled

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

Withdrawn· Eli Lilly logo

Eli Lilly·Phase 3·NCT01870284

A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)

Unknown status·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 2·NCT06242652·250 enrolled

Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice

Completed· AbbVie logo

AbbVie··NCT01768858·96 enrolled

Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study

Unknown status·—·Phase 4·NCT02489760·30 enrolled

Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT02893254·438 enrolled

Ulcerative Colitis8 trials

Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)

Terminated·NNantes University Hospital·N/A·NCT02878083·19 enrolled

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02065622·952 enrolled

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Completed· Roche logo

Roche·Phase 3·NCT02163759·358 enrolled

Show 5 more trials

A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab

Recruiting·GGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives·Phase 4·NCT04183608·238 enrolled

Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis

Completed·VVastra Gotaland Region··NCT06269185·271 enrolled

Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT00573794·592 enrolled

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Completed· Takeda logo

Takeda·Phase 3·NCT02497469·771 enrolled

Completed· Roche logo

Roche·Phase 3·NCT02171429·358 enrolled

Uveitis7 trials

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04088409·30 enrolled

Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis

Not yet recruiting·PPeking Union Medical College Hospital·Phase 4·NCT05105347·130 enrolled

Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis

Unknown status·SSun Yat-sen University·Phase 2·NCT04588818·30 enrolled

Show 4 more trials

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01148225·424 enrolled

Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01124838·261 enrolled

Adalimumab in JIA-associated Uveitis Stopping Trial

Completed·NNisha Acharya·Phase 4·NCT03816397·87 enrolled

Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)

Unknown status·HHeidelberg University·Phase 2/3·NCT00348153·40 enrolled

Hidradenitis Suppurativa7 trials

Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

Completed· AbbVie logo

AbbVie·Phase 3·NCT02904902·15 enrolled

Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa

Completed· AbbVie logo

AbbVie·Phase 3·NCT01635764·508 enrolled

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Completed· UCB logo

UCB·Phase 2·NCT03248531·90 enrolled

Show 4 more trials

A Study of LAD191 in Adults With Hidradenitis Suppurativa

Not yet recruiting·AAlmirall, S.A.·Phase 2·NCT07151937·200 enrolled

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

Completed· AbbVie logo

AbbVie·Phase 4·NCT02808975·206 enrolled

A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04988308·151 enrolled

Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients

Completed· AbbVie logo

AbbVie··NCT02739828·24 enrolled

Moderate to Severe Crohn's Disease6 trials

Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

Completed· AbbVie logo

AbbVie·Phase 2·NCT02015793·30 enrolled

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

Completed·AAbbott·Phase 3·NCT00409682·192 enrolled

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

Completed·AAbbott·Phase 3·NCT00338650·1,000 enrolled

Show 3 more trials

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT02499783·205 enrolled

Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

Completed·AAbbott·Phase 3·NCT00427921·304 enrolled

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT02065570·514 enrolled

Inflammatory Bowel Disease5 trials

Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease

Not yet recruiting·UUniversity Medical Center Groningen·Phase 1/2·NCT07258641·30 enrolled

Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease

Recruiting·UUniversity Medical Center Groningen·Phase 1/2·NCT06117423·21 enrolled

Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

Completed·RRehab Werida·N/A·NCT05291039·56 enrolled

Show 2 more trials

Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)

Completed· AbbVie logo

AbbVie··NCT02750800·427 enrolled

Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)

Completed·EErasmus Medical Center··NCT01971970·45 enrolled

Efficacy and Safety4 trials

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

Completed· Pfizer logo

Pfizer·Phase 4·NCT02187055·1,152 enrolled

The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

Not yet recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT07013838·50 enrolled

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT06498089·124 enrolled

Show 1 more trial

Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA

Completed·CCinnagen·Phase 3·NCT03172325·136 enrolled

Immunogenicity3 trials

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.

Completed· GSK logo

GSK·Phase 1·NCT01899755·45 enrolled

Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

Completed·TTurgut İlaçları A.Ş.·Phase 1·NCT04439929·168 enrolled

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects

Completed·SSamsung Bioepis Co., Ltd.·Phase 1·NCT04514796·188 enrolled

Arthritis3 trials

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT02696785·341 enrolled

Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis

Completed·RRigshospitalet, Denmark·Phase 4·NCT01029847·49 enrolled

Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis

Unknown status·GGoupe d'Etudes et de Recherche Clinique En Rhumatologie·Phase 4·NCT00291915·80 enrolled

Juvenile Idiopathic Arthritis2 trials

Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use

Completed· AbbVie logo

AbbVie·Phase 3·NCT00775437·32 enrolled

Juvenile Idiopathic Arthritis (JIA) Registry

Completed· AbbVie logo

AbbVie··NCT00783510·849 enrolled

Tics2 trials

Pharmacokinetics and Safety in Healthy Volunteers

Completed·SSinocelltech Ltd.·Phase 1·NCT03917628·146 enrolled

Pharmacokinetics and Safety in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02045979·327 enrolled

Treatment2 trials

Treatments Against RA and Effect on FDG-PET/CT

Completed·—·Phase 4·NCT02374021·159 enrolled

Treatment Tapering in JIA With Inactive Disease

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02840175·62 enrolled

Anal fistula2 trials

Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's

Completed·FFoundation for Liver Research·Phase 3·NCT00736983·76 enrolled

Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas

Completed·VVanderbilt University Medical Center·Phase 4·NCT00517296·21 enrolled

Sarcoidosis2 trials

Trial of Adalimumab in Progressive Sarcoidosis

Terminated·UUniversity of Chicago·Phase 2·NCT00311246·11 enrolled

Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis

Withdrawn·WWake Forest University·Phase 2·NCT00690911

Methotrexate1 trial

The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients

Terminated·HHeinrich-Heine University, Duesseldorf·Phase 3·NCT02150473·21 enrolled

Dendritic Cell1 trial

Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy

Unknown status·UUniversity of Padova·Phase 4·NCT01237262·20 enrolled

Vogt-Koyanagi-Harada disease1 trial

A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease

Recruiting·TTianjin Medical University··NCT05590416·15 enrolled

Phase II Clinical Trial1 trial

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Completed·NNYU Langone Health·Phase 2·NCT00814255·32 enrolled

MPA1 trial

Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers

Completed·AAlvotech Swiss AG·Phase 1·NCT03579823·24 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept

Completed·IInnovaderm Research Inc.·Phase 3·NCT00927069·85 enrolled

Fluorescence1 trial

Fluorescence Imaging of IBD and RA Using Adalimumab-800CW

Recruiting·UUniversity Medical Center Groningen·Phase 2·NCT03938701·36 enrolled

Giant Cell Arteritis1 trial

HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00305539·69 enrolled

Adult Subject1 trial

Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects

Completed·SSynermore Biologics Co., Ltd.·Phase 1·NCT03254810·94 enrolled

BPH1 trial

Effects of TNF Blockade on Human BPH/LUTS

Recruiting·EEndeavor Health·Phase 2·NCT06062875·70 enrolled

Bone Resorption1 trial

Bone Resorption, Osteoclastogenesis and Adalimumab

Completed·UUniversité de Sherbrooke·N/A·NCT00814866·28 enrolled

Trial1 trial

Control Crohn Safe Trial

Recruiting·MMaastricht University Medical Center·Phase 4·NCT03917303·158 enrolled

Cohort Study1 trial

One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

Completed· Biogen logo

Biogen··NCT03662919·2,274 enrolled

Real-world Study1 trial

A Real-world Study of Imraldi® Use

Completed· Biogen logo

Biogen··NCT04089514·1,000 enrolled

Maintenance Therapy1 trial

Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)

Withdrawn·PPeter Higgins·Phase 3·NCT01674413

Effectiveness1 trial

Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice

Completed· AbbVie logo

AbbVie··NCT01736189·346 enrolled

Osteomyelitis1 trial

CHronic Nonbacterial Osteomyelitis International Registry

Recruiting·SSeattle Children's Hospital··NCT04725422·2,000 enrolled

Hermansky-Pudlak syndrome1 trial

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00514982

Folliculitis1 trial

Biologics in Folliculitis Decalvans : an Adaptative Trial Research

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT07268534·120 enrolled

Crohn's Disease (CD)1 trial

Triple Combination Therapy in High Risk Crohn's Disease (CD)

Completed· Takeda logo

Takeda·Phase 4·NCT02764762·55 enrolled

Dupuytren's Disease1 trial

Repurposing Anti-TNF for Treating Dupuytren's Disease

Completed·UUniversity of Oxford·Phase 2·NCT03180957·140 enrolled

Clinical Trial1 trial

Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT02912247·183 enrolled

Melanoma1 trial

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Completed· Roche logo

Roche·Phase 1·NCT04551352·20 enrolled

ISS1 trial

Swiss Dermatology Network of Targeted Therapies (SDNTT)

Recruiting·SSwiss Dermatology Network for Targeted Therapies··NCT01706692·1,121 enrolled

COVID-191 trial

Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse

Completed·IIRCCS San Raffaele··NCT05706038·49 enrolled

Netherton syndrome1 trial

Clinical Trial Using Humira in Netherton Syndrome

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02113904·11 enrolled

Tocilizumab1 trial

Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau··NCT02963402·35 enrolled

Unspecified1 trial

Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease

Completed·HHospital Universitari Vall d'Hebron Research Institute·N/A·NCT02539849·38 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 31, 2002

Humira

BLA 125057

Dec 31, 2002

HUMIRA

BLA BLA125057

Oct 30, 2018

ADALIMUMAB

BLA BLA761071

Jul 23, 2019

HADLIMA

BLA BLA761059

May 23, 2023

ADALIMUMAB

BLA BLA761219

Sources

References

[1]
ClinicalTrials.gov — 417 trial records for Adalimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Humira drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Adalimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Adalimumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761219). U.S. Food & Drug Administration.
[6]
PubMed — 10 publications indexed for Adalimumab. U.S. National Library of Medicine.
[7]
SEC EDGAR — Ranbaxy Laboratories Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: TNF-Alpha Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: RRanbaxy Laboratories Limited

Key Publications[6]

"It's taken away the most fundamental things about being human": the lived experience and impact of post-SSRI sexual dysfunction.

Int J Qual Stud Health Well-beingDec 31, 2026DOI: 10.1080/17482631.2026.2717470

Exploring emotional intelligence through emotional journaling: a qualitative study of young students.

Int J Qual Stud Health Well-beingDec 31, 2026DOI: 10.1080/17482631.2026.2688506

Mott-Schottky Interface in Bi(2)Fe(4)O(9)/Ag Boosting Piezocarriers Separation for Hydroxychloroquine Degradation.

ChemSusChemAug 27, 2026DOI: 10.1002/cssc.70959

Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled Trial.

Diabetes Obes MetabAug 13, 2026DOI: 10.1111/dom.71204

Cervical pseudolymphoma following lamotrigine treatment: A clinical vignette.

Epileptic DisordAug 13, 2026DOI: 10.1002/epd2.70321

An Algorithm for the Diagnosis and Treatment of Allergic Contact Dermatitis (ACD).

AllergyAug 13, 2026DOI: 10.1111/all.70479

Exploration of Patient Adherence to Physician Recommendations in Laryngology Clinics.

LaryngoscopeAug 13, 2026DOI: 10.1002/lary.70740

Beyond current standards: combination therapy and emerging targets in diabetic kidney disease.

Kidney Res Clin PractAug 13, 2026DOI: 10.23876/j.krcp.26.234

Enzyme-driven antimicrobial resistance and advancements in sustainable anti-infective strategies.

Crit Rev BiotechnolAug 13, 2026DOI: 10.1080/07388551.2026.2693159

Current trends and advances of microbial biosurfactants in the biomedical and pharmaceutical applications.

Crit Rev BiotechnolAug 13, 2026DOI: 10.1080/07388551.2026.2711971

Humira

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Rheumatoid Arthritis50 trials

Psoriasis25 trials

Adalimumab13 trials

Crohn's Disease12 trials

Psoriatic Arthritis10 trials

Ankylosing Spondylitis9 trials

Ulcerative Colitis8 trials

Uveitis7 trials

Hidradenitis Suppurativa7 trials

Moderate to Severe Crohn's Disease6 trials

Inflammatory Bowel Disease5 trials

Efficacy and Safety4 trials

Immunogenicity3 trials

Arthritis3 trials

Juvenile Idiopathic Arthritis2 trials

Tics2 trials

Treatment2 trials

Anal fistula2 trials

Sarcoidosis2 trials

Methotrexate1 trial

Dendritic Cell1 trial

Vogt-Koyanagi-Harada disease1 trial

Phase II Clinical Trial1 trial

MPA1 trial

Safety and Efficacy1 trial

Fluorescence1 trial

Giant Cell Arteritis1 trial

Adult Subject1 trial

BPH1 trial

Bone Resorption1 trial

Trial1 trial

Cohort Study1 trial

Real-world Study1 trial

Maintenance Therapy1 trial

Effectiveness1 trial

Osteomyelitis1 trial

Hermansky-Pudlak syndrome1 trial

Folliculitis1 trial

Crohn's Disease (CD)1 trial

Dupuytren's Disease1 trial

Clinical Trial1 trial

Melanoma1 trial

ISS1 trial

COVID-191 trial

Netherton syndrome1 trial

Tocilizumab1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Key Publications[6]

Related News